Tempest Therapeutics, Inc.

We are a clinical-stage biotechnology company advancing a pipeline of advanced chimeric antigen receptor T-cell (“CAR-T”) product candidates, including our lead program, TPST-4003, a dual-targeting CD19/B-cell maturation antigen (“BCMA”) in vivo CAR-T product candidate, which we are developing for indications in immunology and oncology. In February 2026, we expanded our pipeline through a strategic transaction under which we acquired rights to a dual-targeting CAR-T platform, which included product candidates with the potential to treat certain blood cancers, solid tumors and immunology indications, including TPST-2003, an autologous CD19/BCMA CAR-T therapy currently in clinical development for relapsed or refractory multiple myeloma and the rare disease, POEMS syndrome.

Current securities

1. S-3 filingSep 25, 2026
2. Entry into a Material Definitive Agreement · Regulation FD DisclosureSep 17, 2026
3. DEFA14A filingSep 16, 2026
4. Submission of Matters to a Vote of Security Holders · Other EventsSep 16, 2026
5. Entry into a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesSep 15, 2026